FPH:NZXFisher & Paykel Healthcare Corporation Limited Analysis
Data as of 2026-03-13 - not real-time
$5.13
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Five Point Holdings appears markedly undervalued with its market price well beneath the discounted cash‑flow estimate and far below the sector’s average price‑to‑earnings multiple. The stock trades below its 20‑day and 50‑day simple moving averages, reinforcing a short‑term downtrend. Momentum indicators such as the relative strength index sit in the lower half of the scale, suggesting limited upside pressure. The MACD line remains under its signal, producing a bearish histogram that aligns with the decreasing volume trend. Despite a steep revenue contraction, the company still generates a healthy gross margin and a profit margin well above 60 %. Its balance sheet shows ample cash reserves, though total debt exceeds cash, resulting in a high debt‑to‑equity ratio.
The recent announcement of a new Hearthstone residential land‑banking partnership with Blue Owl Managed Funds could inject fresh capital and broaden the pipeline. An upcoming earnings release and investor conference provide a near‑term catalyst that may clarify the sustainability of operating cash flows. The firm’s low price‑to‑book ratio and modest beta suggest limited market‑wide volatility, yet the sector’s cyclical nature and California‑specific regulatory environment impose medium‑to‑high risk. Liquidity appears constrained as current trading volume trails the ten‑day average, placing the stock near its identified support level. While dividend yield is zero, the valuation gap offers a compelling entry point for value‑oriented investors willing to weather short‑term price weakness. Overall, the confluence of undervaluation, a strategic partnership, and a clear support zone points to a potential upside if the company can stabilize earnings.
The recent announcement of a new Hearthstone residential land‑banking partnership with Blue Owl Managed Funds could inject fresh capital and broaden the pipeline. An upcoming earnings release and investor conference provide a near‑term catalyst that may clarify the sustainability of operating cash flows. The firm’s low price‑to‑book ratio and modest beta suggest limited market‑wide volatility, yet the sector’s cyclical nature and California‑specific regulatory environment impose medium‑to‑high risk. Liquidity appears constrained as current trading volume trails the ten‑day average, placing the stock near its identified support level. While dividend yield is zero, the valuation gap offers a compelling entry point for value‑oriented investors willing to weather short‑term price weakness. Overall, the confluence of undervaluation, a strategic partnership, and a clear support zone points to a potential upside if the company can stabilize earnings.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- bearish technical momentum
- price near identified support level
- decreasing trading volume
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- undervalued relative to fundamentals
- new land‑banking partnership providing growth catalyst
- potential earnings stabilization after upcoming release
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- significant land asset base with long‑term upside
- value‑oriented pricing metrics
- stable cash position despite leverage
Key Metrics & Analysis
Financial Health
Revenue Growth-52.50%
Profit Margin64.50%
P/E Ratio5.3
ROE8.03%
ROA-0.14%
Debt/Equity21.69
P/B Ratio0.4
Op. Cash Flow$105.2M
Free Cash Flow$-107068624
Industry P/E32.7
Technical Analysis
TrendBearish
RSI36.0
Support$5.08
Resistance$5.70
MA 20$5.42
MA 50$5.48
MA 200$5.73
MACDBearish
VolumeDecreasing
Fear & Greed Index72.48
Valuation
Fair Value$6.24
GradeUndervalued
TypeValue
Risk Assessment
Beta0.80
Volatility30.67%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.